AMENDMENTS

In the claims:

1. (Previously presented) A LM609 CDR-grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$ comprising at least one LM609 CDR-grafted heavy chain polypeptide comprising a variable region amino acid sequence shown in Figure 1A (SEQ ID NO:2), said variable region amino acid sequence having a framework sequence having 88% or greater identity with the framework sequence of SEQ ID NO:2, and at least one LM609 CDR-grafted light chain polypeptide comprising a variable region amino acid sequence shown in Figure 1B (SEQ ID NO:4), said variable region amino acid sequence having a framework sequence having 79% or greater identity with the framework sequence of SEQ ID NO:4, or a functional fragment thereof, said LM609 CDR-grafted antibody or functional fragment thereof having integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity or integrin $\alpha_v\beta_3$-inhibitory activity, wherein said variable region amino acid sequences encoding said heavy and light chain polypeptides are non-mouse sequences.

2. (Previously presented) The LM609 CDR-grafted antibody of claim 1, wherein said functional fragment is selected from the group consisting of Fv, Fab, $F(ab)_2$ and scFV.

3. (Previously presented) A nucleic acid encoding a LM609 CDR-grafted heavy chain polypeptide comprising a LM609 CDR-grafted heavy chain variable region nucleotide sequence, or a modification of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, shown in Figure 1A (SEQ ID NO:1) or a fragment thereof.

4. (Previously presented) The nucleic acid of claim 3, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence, or a modification of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, as the variable region of said LM609 CDR-grafted heavy chain polypeptide (SEQ ID NO:1).

5. (Previously presented) The nucleic acid of claim 3, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence of a CDR of said LM609 CDR-grafted heavy chain polypeptide.

6. (Previously presented) A nucleic acid encoding a LM609 CDR-grafted light chain polypeptide comprising a LM609 CDR-grafted light chain variable region nucleotide sequence, or a modification of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, shown in Figure 1B (SEQ ID NO:3) or a fragment thereof.

7. (Previously presented) The nucleic acid of claim 6, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence, or a modification of said nucleotide sequence wherein said modification does not change the encoded amino acid sequence, as the variable region of said LM609 CDR-grafted light chain polypeptide (SEQ ID NO:3).

8. (Previously presented) The nucleic acid of claim 6, wherein said fragment further comprises a nucleic acid encoding a nucleotide sequence of a CDR of said LM609 CDR-grafted light chain polypeptide.

9. (Previously presented) A nucleic acid encoding a LM609 CDR-grafted antibody heavy chain polypeptide comprising a nucleotide sequence encoding a LM609 CDR-grafted heavy chain variable region amino acid sequence having 88% or greater identity with that shown in Figure 1A (SEQ ID NO:2) or fragment thereof, wherein said variable region amino acid sequence encoding said heavy chain polypeptide is a non-mouse sequence and wherein said nucleic acid encodes a heavy chain polypeptide of an antibody having integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity, or integrin $\alpha_V\beta_3$-inhibitory activity.

10. (Previously presented) The nucleic acid of claim 9, wherein said fragment further comprises a nucleic acid encoding a heavy chain variable region amino acid sequence of said LM609 CDR-grafted heavy chain amino acid sequence.

11. (Previously presented) The nucleic acid of claim 9, wherein said fragment further comprises a nucleic acid encoding a heavy chain CDR amino acid sequence of said LM609 CDR-grafted heavy chain amino acid sequence.

12. (Previously presented) A nucleic acid encoding a LM609 CDR-grafted antibody light chain polypeptide comprising a nucleotide sequence encoding a LM609 CDR-grafted light chain variable region amino acid sequence having 79% or greater identity with that shown in Figure 1B (SEQ ID NO:4) or fragment thereof, wherein said variable region amino

acid sequence encoding said light chain polypeptide is a non-mouse sequence and wherein said nucleic acid encodes a light chain polypeptide of an antibody having integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity, or integrin $\alpha_V\beta_3$-inhibitory activity.

13. (Previously presented) The nucleic acid of claim 12, wherein said fragment further comprises a nucleic acid encoding a light chain variable region amino acid sequence of said LM609 CDR-grafted light chain amino acid sequence.

14. (Previously presented) The nucleic acid of claim 12, wherein said fragment further comprises a nucleic acid encoding a light chain CDR amino acid sequence of said LM609 CDR-grafted light chain amino acid sequence.

15. (Previously presented) A LM609 CDR-grafted heavy chain polypeptide comprising a variable region amino acid sequence having 88% or greater identity with that shown in Figure 1A (SEQ ID NO:2) or functional fragment thereof, wherein said variable region amino acid sequence encoding said heavy chain polypeptide is a non-mouse sequence and wherein an antibody comprising said heavy chain polypeptide has integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity, or integrin $\alpha_V\beta_3$-inhibitory activity.

16. (Previously presented) The LM609 CDR-grafted heavy chain polypeptide of claim 15, wherein said functional fragment comprises a variable chain polypeptide or a CDR polypeptide.

17. (Previously presented) A LM609 CDR-grafted light chain polypeptide comprising a variable region amino acid sequence having 79% or greater identity with that shown in Figure 1B (SEQ ID NO:4) or a functional fragment thereof, wherein said variable region amino acid sequence encoding said light chain polypeptide is a non-mouse sequence and wherein an antibody comprising said light chain polypeptide has integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity, or integrin $\alpha_V\beta_3$-inhibitory activity.

18. (Previously presented) The LM609 CDR-grafted light chain polypeptide of claim 17, wherein said functional fragment comprises a variable chain polypeptide or a CDR polypeptide.

19. (Withdrawn) A method of inhibiting a function of $\alpha_V\beta_3$ comprising contacting $\alpha_V\beta_3$ with a LM609 grafted antibody or a functional fragment thereof under conditions which allow binding of LM609 grafted antibodies to $\alpha_V\beta_3$.

20. (Withdrawn) The method of claim 19, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)2 and scFV.

21. (Withdrawn) The method of claim 19, wherein said function of $\alpha_V\beta_3$ is binding of $\alpha_V\beta_3$ to a ligand.

22. (Withdrawn) The method of claim 19, wherein said function of $\alpha_V\beta_3$ is integrin mediated signal transduction.

23. (Withdrawn) A method of treating an $\alpha_V\beta_3$-mediated disease comprising administering an effective amount of a LM609 grafted antibody or a functional fragment thereof under conditions which allow binding to $\alpha_V\beta_3$.

24. (Withdrawn) The method of claim 23, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)2 and scFV.

25. (Withdrawn) The method of claim 23, wherein said $\alpha_V\beta_3$-mediated disease is angiogenesis or restenosis.

26. (Previously presented) A LM609 CDR-grafted antibody exhibiting selective binding affinity to $\alpha_V\beta_3$ comprising at least one LM609 CDR-grafted heavy chain polypeptide encoded by a LM609 CDR-grafted heavy chain variable region nucleotide sequence referenced as SEQ ID NO:1, or a modification thereof, and at least one LM609 CDR-grafted light chain polypeptide encoded by a LM609 CDR-grafted light chain variable region nucleotide sequence referenced as SEQ ID NO:3, or a modification thereof, or a functional fragment of said LM609 CDR-grafted antibody, said LM609 CDR-grafted antibody or functional fragment thereof having integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity or integrin $\alpha_V\beta_3$-inhibitory activity.

27. (Previously presented) The LM609 CDR-grafted antibody of claim 26, wherein said functional fragment is selected from the group consisting of Fv, Fab, $F(ab)_2$ and scFV.

28. (Previously presented) A LM609 CDR-grafted heavy chain polypeptide comprising a heavy chain polypeptide, or a functional fragment thereof, encoded by a LM609 CDR-grafted heavy chain variable region nucleotide sequence referenced as SEQ ID NO:1, or a modification thereof.

29. (Previously presented) The LM609 CDR-grafted heavy chain polypeptide of claim 28, wherein said functional fragment comprises a variable chain polypeptide or a CDR polypeptide.

30. (Previously presented) A LM609 CDR-grafted light chain polypeptide comprising a light chain polypeptide, or a functional fragment thereof, encoded by a LM609 CDR-grafted light chain variable region nucleotide sequence referenced as SEQ ID NO:3, or a modification thereof.

31. (Previously presented) The LM609 CDR-grafted heavy chain polypeptide of claim 30, wherein said functional fragment comprises a variable chain polypeptide or a CDR polypeptide.

32. (Previously presented) The antibody of claim 2, wherein said functional fragment is a Fab

33. (Previously presented) A LM609 CDR-grafted antibody, or a functional fragment thereof, exhibiting selective binding affinity to $\alpha_v\beta_3$ comprising at least one LM609 CDR-grafted heavy chain polypeptide comprising a variable region amino acid sequence referenced as SEQ ID NO:2, or a modification thereof, and at least one LM609 CDR-grafted light chain polypeptide comprising a variable region amino acid sequence referenced as SEQ ID NO:4, or a modification thereof, said LM609 CDR-grafted antibody or functional fragment thereof being a non-mouse antibody or functional fragment and having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$-inhibitory activity.

34. (Previously presented) The LM609 CDR-grafted antibody of claim 33, wherein said functional fragment is selected from the group consisting of Fv, Fab, $F(ab)_2$ and scFV.

35. (Previously presented) A nucleic acid encoding the LM609 CDR-grafted antibody of claim 33.

36. (Previously presented) A LM609 CDR-grafted heavy chain polypeptide, or functional fragment thereof, comprising a variable region amino acid sequence referenced as SEQ ID NO:2, or a modification thereof, wherein an antibody or functional fragment comprising said heavy chain polypeptide is a non-mouse antibody or functional fragment and has integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity, or integrin $\alpha_V\beta_3$-inhibitory activity.

37. (Previously presented) A nucleic acid encoding the LM609 CDR-grafted heavy chain polypeptide of claim 36.

38. (Previously presented) A LM609 CDR-grafted light chain polypeptide, or a functional fragment thereof, comprising a variable region amino acid sequence referenced as SEQ ID NO:4, or a modification thereof, wherein an antibody or functional fragment thereof comprising said light chain polypeptide is a non-mouse antibody or functional fragment and has integrin $\alpha_V\beta_3$ binding activity, integrin $\alpha_V\beta_3$ binding specificity, or integrin $\alpha_V\beta_3$-inhibitory activity.

39. (Previously presented) A nucleic acid encoding the LM609 CDR-grafted light chain polypeptide of claim 38.